FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381337468> ?p ?o ?g. }

• W4381337468 abstract "Kidney hypoxia has been proposed as key pathophysiological mechanism in the development of chronic kidney disease, potentially stemming from a mismatch between oxygen delivery and oxygen consumption. SGLT2i are kidney protective drugs that initially lower glomerular filtration rate (GFR). Accordingly, we hypothesized that SGLT2i lower kidney oxygen consumption by reducing GFR and associated tubular workload. Twenty adults with T2D (sex 80% male, age 68±6 years, BMI 30±4 kg/m2, HbA1c 7.5±0.9%, eGFR 76 ± 11 mL/min/1.73m2) received a 4-week treatment with SGLT2i ertugliflozin (ERTU) and matched placebo (PLB) in a randomized, double-blind cross-over study. Participants were treated with metformin and received maximal tolerable dose of an angiotensin receptor blocker. Whole-kidney oxygen consumption (Kmono) was measured by PET using 11C-acetate. GFR was measured by gold-standard iohexol clearance. Tubular sodium transport (TNa) was calculated by kidney sodium load (([arterial Na]*mGFR) - urinary sodium excretion). Kidney efficiency calculated as TNa/ Kmono. GFR was lower during ERTU (94 ± 14 mL/min) vs. PLB (99 ± 15 mL/min) treatment (p=0.02). Kmono was 0.086 ± 0.006 min-1 during ERTU and 0.091 ± 0.009 min-1 during PLB (p&lt;0.01). Kidney sodium load (12.9 ± 1.90 vs 13.7 ± 2.22 mmol/min) and TNa (12.7 ± 1.87 vs 13.6 ± 2.18 mmol/min) were lower during ERTU (p=0.02 for both), while urinary sodium excretion (p=0.1) and TNa/ Kmono remained unchanged (p=0.7). TNa strongly associated with Kmono (r=0.50; p&lt;0.0001). In conclusion, SGLT2i lowers mGFR, TNa, and kidney oxygen consumption, potentially decreasing hypoxia risk. SGLT2i treatment did not lower overall kidney efficiency, despite the ATP efficiency of cortical sodium transport. Additional data on cortex and medulla-specific oxygen consumption and multiparametric kidney MRI data will be presented at ADA. Disclosure A. Hesp: None. L. I. P. Snel: None. P. Schober: None. L. A. Schwarte: None. R. Boellaard: None. P. Bjornstad: Advisory Panel; AstraZeneca. Consultant; Bayer Inc., Bristol-Myers Squibb Company. Advisory Panel; Novo Nordisk, Lilly, Horizon Therapeutics plc, Boehringer Ingelheim (Canada) Ltd., LG Chem. D. van Raalte: Consultant; Boehringer Ingelheim and Eli Lilly Alliance, AstraZeneca, Merck & Co., Inc. Research Support; Boehringer Ingelheim and Eli Lilly Alliance, AstraZeneca, Merck & Co., Inc. Funding MSD" @default.
• W4381337468 created "2023-06-21" @default.
• W4381337468 creator A5029713359 @default.
• W4381337468 creator A5035267054 @default.
• W4381337468 creator A5036425382 @default.
• W4381337468 creator A5040462237 @default.
• W4381337468 creator A5052192929 @default.
• W4381337468 creator A5059753123 @default.
• W4381337468 creator A5066151252 @default.
• W4381337468 date "2023-06-20" @default.
• W4381337468 modified "2023-09-26" @default.
• W4381337468 title "7-LB: Sodium–Glucose Cotransporter-2 Inhibitors (SGLT2i) Decrease Kidney Oxygen Consumption in Adults with Type 2 Diabetes (T2D)—A Randomized Clinical Trial Using 11C-Acetate Positron Emission Tomography (PET) Imaging" @default.
• W4381337468 doi "https://doi.org/10.2337/db23-7-lb" @default.
• W4381337468 hasPublicationYear "2023" @default.
• W4381337468 type Work @default.
• W4381337468 citedByCount "0" @default.
• W4381337468 crossrefType "journal-article" @default.
• W4381337468 hasAuthorship W4381337468A5029713359 @default.
• W4381337468 hasAuthorship W4381337468A5035267054 @default.
• W4381337468 hasAuthorship W4381337468A5036425382 @default.
• W4381337468 hasAuthorship W4381337468A5040462237 @default.
• W4381337468 hasAuthorship W4381337468A5052192929 @default.
• W4381337468 hasAuthorship W4381337468A5059753123 @default.
• W4381337468 hasAuthorship W4381337468A5066151252 @default.
• W4381337468 hasConcept C10146269 @default.
• W4381337468 hasConcept C126322002 @default.
• W4381337468 hasConcept C126894567 @default.
• W4381337468 hasConcept C134018914 @default.
• W4381337468 hasConcept C159641895 @default.
• W4381337468 hasConcept C2777180221 @default.
• W4381337468 hasConcept C2778653478 @default.
• W4381337468 hasConcept C2780091579 @default.
• W4381337468 hasConcept C2780323712 @default.
• W4381337468 hasConcept C555293320 @default.
• W4381337468 hasConcept C71924100 @default.
• W4381337468 hasConceptScore W4381337468C10146269 @default.
• W4381337468 hasConceptScore W4381337468C126322002 @default.
• W4381337468 hasConceptScore W4381337468C126894567 @default.
• W4381337468 hasConceptScore W4381337468C134018914 @default.
• W4381337468 hasConceptScore W4381337468C159641895 @default.
• W4381337468 hasConceptScore W4381337468C2777180221 @default.
• W4381337468 hasConceptScore W4381337468C2778653478 @default.
• W4381337468 hasConceptScore W4381337468C2780091579 @default.
• W4381337468 hasConceptScore W4381337468C2780323712 @default.
• W4381337468 hasConceptScore W4381337468C555293320 @default.
• W4381337468 hasConceptScore W4381337468C71924100 @default.
• W4381337468 hasIssue "Supplement_1" @default.
• W4381337468 hasLocation W43813374681 @default.
• W4381337468 hasOpenAccess W4381337468 @default.
• W4381337468 hasPrimaryLocation W43813374681 @default.
• W4381337468 hasRelatedWork W1978634877 @default.
• W4381337468 hasRelatedWork W2005084305 @default.
• W4381337468 hasRelatedWork W2016264464 @default.
• W4381337468 hasRelatedWork W2021846613 @default.
• W4381337468 hasRelatedWork W2028993205 @default.
• W4381337468 hasRelatedWork W2033313326 @default.
• W4381337468 hasRelatedWork W2042033030 @default.
• W4381337468 hasRelatedWork W2127085070 @default.
• W4381337468 hasRelatedWork W2744240433 @default.
• W4381337468 hasRelatedWork W4240148004 @default.
• W4381337468 hasVolume "72" @default.
• W4381337468 isParatext "false" @default.
• W4381337468 isRetracted "false" @default.
• W4381337468 workType "article" @default.